PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.
Current treatment options in oncology. 2024 Jan 25 [Epub ahead of print]
Adam B Weiner, Raag Agrawal, Luca F Valle, Ida Sonni, Amar U Kishan, Matthew B Rettig, Steven S Raman, Jeremie Calais, Paul C Boutros, Robert E Reiter
Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. ., Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA., Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.